Tel Aviv University together with Tel Aviv Medical Center (Ichilov) and Electra E&M Company won a grant of 4.5 million NIS from the Ministry of Economy and Industry to promote the biomed industry in Israel. The grant is part of a project with a total scope of NIS 15 million to establish an advanced facility for the production of viral vectors.
The announcement of winning the grant took place at a festive event held at the Steinhardt Museum of Nature. Participated in the event: Minister of Economy and Industry, Nir Barkat; CEO of the University, Gadi Frank; CEO of the Tel Aviv Medical Center, E.S. Surasky (Ichilov), Prof. Eli Shaparkar; CEO of Electra E&M, Tal Oron; and researchers from the Faculty of Medical and Health Sciences, who lead the project, Prof. Ariel Monitz and Prof. Moti Gerlitz.
The grant will be provided within the framework of a new plan of the Ministry of Economy and Industry to invest in infrastructure in the fields of high-tech and deep-tech; The plan, in collaboration with the investors, will be carried out with a total investment of about 220 NIS
Minister of Economy and Industry, Nir Barkat: "Together with the business sector, we lay infrastructure to accelerate growth and strengthen @TAG's position as a leader in global entrepreneurship and innovation. The new plan will use the infrastructure for the growth of new companies, to create quality jobs and contribute to the increase of exports. The impressive response from the ground to the Reader's Voice indicates that we are on the right track, and 2025 will be a year of accelerated growth in general and export in particular, however, as part of a vision to increase Israeli exports from one hundred and fifty billion dollars to one trillion dollars exports per year in about fifteen years. "
CEO of Tel Aviv Ichilov Medical Center, Prof. Eli Shaparkar: "Ichilov is proud to lead together with the university innovation in the field of biomedical at the national and global level. Setting up the facility funded by the Ministry of the Economy is another milestone in our ability to provide independence and continuity to research in Israel and will allow us significant breakthroughs in the field of advanced therapies for the benefit of patients in Israel and in the world. ״
Tel Aviv University and Ichilov explain that the purpose of the project is to respond to the global shortage of viral vectors, essential for clinical trials and groundbreaking treatments in the field of Cell and Gene Therapies (GCT) - which provide innovative solutions to diseases such as cancer, infectious diseases and inflammatory diseases. The new facility, which will operate according to the GMP standard, will provide advanced technological solutions for research and industry, and will be a basis for expanding international cooperation and attracting foreign investment in the field.
Prof. Moti Garlitz and Ariel Monitz from the Faculty of Health Sciences and Medicine at Tel Aviv University: "After two years of strenuous work behind the scenes we are happy to see that the state recognizes the essential need and is helping us move from the planning stage to the execution stage." This is a first and important step that will promote the industry in Israel in the field of the GCT and maintain the operational independence of the economy.
Ofer Logasi, CEO of the Tel Aviv University Economic Society: "This project is another step in the economic society's efforts to harness the vast knowledge accumulated in the university faculty for the benefit of the development of industry and the economy in Israel. ״